India, Nov. 18 -- Biocon Limited has received European Commission (EC) marketing authorisation for Pebrilzo®, its pertuzumab biosimilar, for treating HER2-positive breast cancer across multiple disease stages in the European Union.

The approval makes Biocon's pertuzumab the first biosimilar to receive EC authorisation under the European Medicines Agency's (EMA) new tailored clinical approach, following a positive CHMP opinion on September 17, 2026.

With this approval, pertuzumab becomes Biocon's fifth oncology biosimilar approved in both Europe and the United States, strengthening its global oncology portfolio and expanding access to affordable biologic treatments.

The biosimilar will be available as a 420 mg concentrate for infusion...